Takeda Pharmaceutical reveals Phase 3 study data for Soticlestat (TAK-935) in treating Dravet and Lennox-Gastaut syndromes. In 2021, Ovid Therapeutics out licensed the drug.
China's BYD has made a name for itself in the highly competitive Chinese auto market and the fact that Berkshire picked the company's stock over Tesla is a testament to its strength.